DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Sesmilo G, Fairfield WP, Katznelson L. et al.
Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
J Clin Endocr Metab 2002;
87: 1692-1699
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.